Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
olvimulogene nanivacirepvec
- Development stage
- Phase 3
- Lead developer
- Genelux
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
- Administration
- Intravenous, Intraperitoneal, Intrapleural, Intratumoral
01
Overview
Olvimulogene nanivacirepvec (Olvi-Vec) is a proprietary, genetically modified strain of the oncolytic vaccinia virus developed by Genelux Corporation. It is designed to selectively infect and replicate within malignant cells, leading to direct tumor cell lysis (oncolysis) and the induction of immunogenic cell death. This process triggers a systemic anti-tumor immune response and remodels the tumor microenvironment. A key clinical feature of Olvi-Vec is its ability to resensitize tumors to platinum-based chemotherapy, particularly in patients with platinum-resistant or refractory disease. It is currently being evaluated in a Phase 3 registrational trial for platinum-resistant/refractory ovarian cancer and in Phase 2 trials for non-small cell lung cancer and small cell lung cancer.
- Brand names
- Olvi-Vec
- Other names
- olvimulogene nanivacirepvec
Beyond the preview
Go deeper on olvimulogene nanivacirepvec.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on olvimulogene nanivacirepvec.